A Strategic Guide to Improve and De-Risk Vaccine Development: CEPI’s CMC Framework

References

1. 1.↵
   CEPI 2.0 and the 100 Days Mission. CEPI Web site. https://100days.cepi.net/ (accessed March 8, 2024).
2. 2.↵
   1. Saville M.,
   2. Cramer J. P.,
   3. Downham M.,
   4. Hacker A.,
   5. Lurie N.,
   6. Van der Veken L.,
   7. Whelan M.,
   8. Hatchett R.

   Delivering Pandemic Vaccines in 100 Days—What Will It Take? N. Engl. J. Med 2022, 387 (2), e3.

   OpenUrlPubMed
3. 3.↵
   1. Black S.,
   2. Bloom D. E.,
   3. Kaslow D. C.,
   4. Pecetta S.,
   5. Rappuoli R.

   Transforming Vaccine Development. Semin. Immunol. 2020, 50, 101413

   OpenUrlPubMed
4. 4.↵
   1. McGoldrick M.,
   2. Gastineau T.,
   3. Wilkinson D.,
   4. Campa C.,
   5. De Clercq N.,
   6. Mallia-Milanes A.,
   7. Germay O.,
   8. Krishnan J.,
   9. Van Ooij M.,
   10. Thien M. P.,
   11. Mlynarczyk P. J.,
   12. Saltus E.,
   13. Wauters F.,
   14. Juvin P.,
   15. Clenet D.,
   16. Basso A.,
   17. Dellepiane N.,
   18. Pagliusi S.,
   19. de Moraes Stávale M. C.,
   20. Sivaramakrishnan V. H.,
   21. Desai S.

   How to Accelerate the Supply of Vaccines to All Populations Worldwide? Part II: Initial Industry Lessons Learned and Detailed Technical Reflections Leveraging the COVID-19 Situation. Vaccine 2022, 40 (9), 1223–1230.

   OpenUrlPubMed
5. 5.↵
   1. Butler D.

   Translational Research: Crossing the Valley of Death. Nature 2008, 453 (7197), 840–842.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Witek T. J. Jr.

   , How the Global COVID-19 Pandemic Brought Drug and Vaccine Development into the Public Mainstream. Pharm. Med. 2021, 35 (5), 287–295.

   OpenUrl
7. 7.↵
   1. Hutubessy R.,
   2. Lauer J. A.,
   3. Giersing B.,
   4. Sim S. Y.,
   5. Jit M.,
   6. Kaslow D.,
   7. Botwright S.

   The Full Value of Vaccine Assessments (FVVA): A Framework for Assessing and Communicating the Value of Vaccines for Investment and Introduction Decision-Making. BMC Med. 2023, 21 (1), 229.

   OpenUrlPubMed
8. 8.↵
   Traversing The Valley of Death. Nat. Rev. Bioeng. 2023, 1, 875.

   OpenUrl
9. 9.↵
   1. O'Brien K. L.,
   2. Binka F.,
   3. Marsh K.,
   4. Abramson J. S.

   Mind the Gap: Jumping from Vaccine Licensure to Routine Use. Lancet 2016, 387 (10031), 1887–1889.

   OpenUrlPubMed
10. 10.↵
    1. Castellanos M. M.,
    2. Gressard H.,
    3. Li X.,
    4. Magagnoli C.,
    5. Moriconi A.,
    6. Stranges D.,
    7. Strodiot L.,
    8. Tello Soto M.,
    9. Zwierzyna M.,
    10. Campa C.

    CMC Strategies and Advanced Technologies for Vaccine Development to Boost Acceleration and Pandemic Preparedness. Vaccines 2023, 11 (7), 1153.

    OpenUrlPubMed
11. 11.↵
    Developing a Phase-Appropriate CMC Development Plan for Small Biotechs. Enkrisi Web site. https://enkrisi.com/2023/08/02/vol-73-developing-a-phase-appropriate-cmc-development-plan-for-small-biotechs/ (accessed March 8, 2024).
12. 12.↵
    1. Simianu M.

    Phase-Appropriate Frameworks at the Intersection of CMC and cGMP Pathways, 2017. https://www.pharmoutsourcing.com/Featured-Articles/339550-Phase-Appropriate-Frameworks-at-the-Intersection-of-CMC-and-cGMP-Pathways/ (accessed March 8, 2024).
13. 13.↵
    UK Vaccine R&D Network. UKRI Vaccine Development Process Map. https://www.vaccinedevelopment.org.uk/index.html (accessed March 8, 2024).
14. 14.↵
    CHAI Go-to-Market Toolbox for DCVMs. DCVMN Web site. https://dcvmn.org/chai-go-to-market-toolbox-for-dcvms/ (accessed March 8, 2024).
15. 15.↵
    International Conference for Harmonisation, Quality Guideline Q1A(R2): Stability Testing of New Drug Substances and Products. ICH: Geneva, 2003.
16. 16.↵
    International Conference for Harmonisation, Quality Guideline Q1B: Photostability Testing of New Drug Substances and Products. ICH: Geneva, 1996.
17. 17.↵
    International Conference for Harmonisation, Quality Guideline Q1D: Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products. ICH: Geneva, 2002.
18. 18.↵
    International Conference for Harmonisation, Quality Guideline Q2(R2): Validation of Analytical Procedures. ICH: Geneva, 2023.
19. 19.↵
    International Conference for Harmonisation, Quality Guideline Q3A(R2): Impurities in New Drug Substances. ICH: Geneva, 2006.
20. 20.↵
    International Conference for Harmonisation, Quality Guideline Q3B(R2): Impurities in New Drug Products. ICH: Geneva, 2006.
21. 21.↵
    International Conference for Harmonisation, Quality Guideline Q3C(R8): Impurities: Guideline for Residual Solvents. ICH: Geneva, 2022.
22. 22.↵
    International Conference for Harmonisation, Quality Guideline Q3D(R2): Elemental Impurities. ICH: Geneva, 2022.
23. 23.↵
    International Conference for Harmonisation, Quality Guideline Q5A(R2): Quality of Biotechnological Products: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. ICH: Geneva, 2023.
24. 24.↵
    International Conference for Harmonisation, Quality Guideline Q5B: Quality of Biotechnological Products: Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products. ICH: Geneva, 1995.
25. 25.↵
    International Conference for Harmonisation, Quality Guideline Q5C: Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products. ICH: Geneva, 1995.
26. 26.↵
    International Conference for Harmonisation, Quality Guideline Q5D: Derivation and Characterisation of Cell Substrates Used for Production of Biotechnological/Biological Products. ICH: Geneva, 1997.
27. 27.↵
    International Conference for Harmonisation, Quality Guideline Q5E: Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process. ICH: Geneva, 2004.
28. 28.↵
    International Conference for Harmonisation, Quality Guideline Q6A: Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. ICH: Geneva, 1999.
29. 29.↵
    International Conference for Harmonisation, Quality Guideline Q6B: Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH: Geneva, 1999.
30. 30.↵
    International Conference for Harmonisation, Quality Guideline Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. ICH: Geneva, 2000.
31. 31.↵
    International Conference for Harmonisation, Quality Guideline Q8(R2): Pharmaceutical Development. ICH: Geneva, 2009.
32. 32.↵
    International Conference for Harmonisation, Quality Guideline Q9: Quality Risk Management. ICH: Geneva, 2023.
33. 33.↵
    International Conference for Harmonisation, Quality Guideline Q10: Pharmaceutical Quality System. ICH: Geneva, 2008.
34. 34.↵
    International Conference for Harmonisation, Quality Guideline Q11: Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities). ICH: Geneva, 2012.
35. 35.↵
    International Conference for Harmonisation, Quality Guideline Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management. ICH: Geneva, 2019.
36. 36.↵
    International Conference for Harmonisation, Quality Guideline Q13: Continuous Manufacturing of Drug Substances and Drug Products. ICH: Geneva, 2022.
37. 37.↵
    International Conference for Harmonisation, Quality Guideline Q14: Analytical Procedure Development. ICH: Geneva, 2023.
38. 38.↵
    European Commission, EudraLex—The Rules Governing Medicinal products in the European Union, Volume 4: Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 13: Investigational Medicinal Products. European Commission: Brussels, 2010.
39. 39.↵
    European Medicines Agency, Guideline on Quality Aspects Included in the Product Information for Vaccines for Human Use; EMA/CHMP/BWP/133540/2017; EMA: London, 2018.
40. 40.↵
    European Medicines Evaluation Agency, Guideline on Adjuvants in Vaccines for Human Use; EMEA/CHMP/VEG/134716/2004; EMEA: London, 2005.
41. 41.↵
    European Medicines Agency, Guideline on Quality Aspects Included in the Product Information for Vaccines for Human Use—Revision 1; EMA/CHMP/BWP/133540/2017; EMA: London, 2018.
42. 42.↵
    European Medicines Agency, Guideline on Quality, Non-Clinical and Clinical Aspects of Live Recombinant Viral Vectored Vaccines; EMA/CHMP/VWP/141697/2009; EMA: London, 2010.
43. 43.↵
    European Medicines Agency, Guideline on Process Validation for the Manufacture of Biotechnology-Derived Active Substances and Data to be Provided in the Regulatory Submission; EMA/CHMP/BWP/187338/2014; EMA: London, 2016.
44. 44.↵
    European Medicines Agency, Guideline on Comparability of Biotechnology-Derived Medicinal Products after a Change in the Manufacturing Process—Non-Clinical and Clinical Issues; EMA/CHMP/BMWP/101695/2006; EMA: London, 2007.
45. 45.↵
    U.S. Food and Drug Administration, Guidance for Industry: Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2001.
46. 46.↵
    U.S. Food and Drug Administration, Guidance for Industry: Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for a Vaccine or Related Product. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 1999.
47. 47.↵
    U.S. Food and Drug Administration, Guidance for Industry: General Principles for the Development of Vaccines to Protect Against Global Infectious Diseases. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2011.
48. 48.↵
    U.S. Food and Drug Administration, Guidance for Industry: Current Good Manufacturing Practice for Phase 1 Investigational Drugs. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2008.
49. 49.↵
    U.S. Food and Drug Administration, Guidance for Industry: INDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information. Center for Drug Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2003.
50. 50.↵
    U.S. Food and Drug Administration, Guidance for Industry: Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2010.
51. 51.↵
    U.S. Food and Drug Administration, Guidance for Industry: Considerations for Plasmid DNA Vaccines for Infectious Disease Indications. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2007.
52. 52.↵
    U.S. Food and Drug Administration, Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2017.
53. 53.↵
    U.S. Food and Drug Administration, Guidance for Industry: Early Clinical Trials with Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2016.
54. 54.↵
    U.S. Food and Drug Administration, Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2004.
55. 55.↵
    U.S. Food and Drug Administration, Guidance for Industry: Comparability Protocols for Human Drugs and Biologics: Chemistry, Manufacturing, and Controls Information. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2016.
56. 56.↵
    U.S. Food and Drug Administration, Guidance for Industry: Analytical Procedures and Methods Validation for Drugs and Biologics. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2015.
57. 57.↵
    U.S. Food and Drug Administration, Guidance for Industry: Process Validation: General Principles and Practices. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2011.
58. 58.↵
    U.S. Food and Drug Administration, Guidance for Industry: Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2006.
59. 59.↵
    World Health Organization, Annex 3: WHO Good Manufacturing Practices for Pharmaceutical Products: Main Principles; WHO Technical Report Series No. 961; WHO: Geneva, 2011.
60. 60.↵
    WHO Expert Committee on Specifications for Pharmaceutical Preparations: Fifty-Fifth Report; WHO Technical Report Series No. 1033; WHO: Geneva, 2021.
61. 61.↵
    World Health Organization, Evaluation of the Quality, Safety and Efficacy of Messenger RNA Vaccines for the Prevention of Infectious Diseases: Regulatory Considerations. WHO: Geneva, 2021.
62. 62.↵
    World Health Organization, Supplement 14—Transport Route Profiling Qualification. WHO: Geneva, 2015.
63. 63.↵
    World Health Organization, Guidelines for National Authorities on Quality Assurance for Biological Products, Annex 2; WHO Technical Report Series No. 822; WHO: Geneva, 1991.
64. 64.↵
    World Health Organization, Regulation and Licensing of Biological Products in Countries with Newly Developing Regulatory Authorities, Annex 1; WHO Technical Report Series No. 858; WHO: Geneva, 1994.
65. 65.↵
    1. King M. L.

    How Manufacturing Won or Lost the COVID-19 Vaccine Race. Vaccine 2024, 42 (5), 1004–1012.

    OpenUrlPubMed
66. 66.↵
    1. Fontanillo M.,
    2. Paulick K.,
    3. Poda P.,
    4. Silberzahn T.

    Out of the Shadows: A Brighter Future for Pharma Technical Development, 2022. https://www.mckinsey.com/industries/life-sciences/our-insights/out-of-the-shadows-a-brighter-future-for-pharma-technical-development#/ (accessed March 8, 2024).
67. 67.↵
    1. Popkin M. E.,
    2. Goese M.,
    3. Wilkinson D.,
    4. Finnie S.,
    5. Flanagan T.,
    6. Campa C.,
    7. Clinch A.,
    8. Teasdale A.,
    9. Lennard A.,
    10. Cook G.,
    11. Mohan G.,
    12. Osborne M. D.

    Chemistry Manufacturing and Controls Development, Industry Reflections on Manufacture, and Supply of Pandemic Therapies and Vaccines. AAPS J. 2022, 24 (6), 101.

    OpenUrlPubMed
68. 68.↵
    1. Higgins M. F.,
    2. Abu-Absi N.,
    3. Gontarz E.,
    4. Gorr I. H.,
    5. Kaiser K.,
    6. Patel P.,
    7. Ritacco F.,
    8. Sheehy P.,
    9. Thangaraj B.,
    10. Gill T.

    Accelerated CMC Workflows to Enable Speed to Clinic in the COVID-19 Era: A Multi-Company View from the Biopharmaceutical Industry. Biotechnol. Prog. 2023, 39 (2), e3321.

    OpenUrl
69. 69.↵
    EFPIA White Paper on CMC Development, Manufacture and Supply of Pandemic COVID-19 Therapies and Vaccines, 2020. https://www.efpia.eu/media/554681/cmc-development-manufacture-and-supply-of-covid-19-therapies-and-vaccines.pdf (accessed March 8, 2024).
70. 70.↵
    The Global Health Network Web site. https://epi.tghn.org/vaccine-development/ (accessed September 28, 2023)